Soleno Therapeutics, Neurocrine Bioscience Company

Soleno Therapeutics, a Neurocrine Biosciences company, develops therapies for rare genetic disorders. The first and only therapy for the treatment of hyperphagia in #PraderWilliSyndrome received full FDA-approval in March 2025.

C-US-PWS-00066